| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RAB5B |
| Uniprot No | P61020 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-215aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMTSRSTARPNGQPQASKICQFKLVLLG ESAVGKSSLVLRFVKGQFHEYQESTIGAAFLTQSVCLDDTTVKFEIWDTA GQERYHSLAPMYYRGAQAAIVVYDITNQETFARAKTWVKELQRQASPSIV IALAGNKADLANKRMVEYEEAQAYADDNSLLFMETSAKTAMNVNDLFLAI AKKLPKSEPQNLGGAAGRSRGVDLHEQSQQNKSQCCSN |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RAB5B重组蛋白的3篇模拟参考文献示例(实际文献需根据具体研究补充)：
1. **文献名称**: "Functional characterization of RAB5B in endosomal membrane trafficking"
**作者**: Smith A, et al.
**摘要**: 该研究通过构建RAB5B重组蛋白，解析了其在早期内体膜运输中的调控机制，发现RAB5B通过结合效应蛋白EEA1促进内体融合，并利用体外重组系统验证了其GTPase活性对囊泡运输的调控作用。
2. **文献名称**: "RAB5B overexpression enhances EGFR signaling in cancer cells"
**作者**: Chen L, et al.
**摘要**: 文章利用重组RAB5B蛋白在肺癌细胞中过表达，证明其通过加速EGFR内吞和再循环，增强下游MAPK信号通路，促进肿瘤细胞增殖和迁移。
3. **文献名称**: "RAB5B interacts with APPL1 to regulate autophagy"
**作者**: Wang Y, et al.
**摘要**: 通过重组RAB5B和APPL1蛋白的共沉淀实验，揭示了二者在自噬体形成中的相互作用，并证明RAB5B-APPL1复合物通过mTOR通路调控细胞应激状态下的自噬活性。
注：以上为示例性内容，实际文献需通过PubMed、Google Scholar等平台检索确认。
Rab5B is a member of the Rab GTPase family, a group of small proteins that act as molecular switches regulating intracellular membrane trafficking. Specifically, Rab5B is involved in early endosome dynamics, playing a critical role in clathrin-mediated endocytosis, endosome fusion, and cargo sorting. It cycles between an active GTP-bound state and an inactive GDP-bound state, interacting with effector proteins like EEA1 and Rabaptin-5 to mediate vesicle docking and membrane fusion. While sharing ~80% sequence identity with its isoforms Rab5A and Rab5C, Rab5B exhibits distinct expression patterns and regulatory roles in certain tissues, suggesting functional diversification.
Recombinant Rab5B proteins are engineered in vitro using expression systems (e.g., E. coli, mammalian cells) to study its structure, biochemical interactions, and role in cellular pathways. These purified proteins retain GTPase activity and binding capacity, enabling researchers to dissect mechanisms of endosomal trafficking in controlled experiments. Rab5B dysfunction has been implicated in diseases, including cancer (e.g., altered trafficking in tumor progression) and neurodegenerative disorders (e.g., disrupted synaptic vesicle recycling). Its recombinant form is pivotal for developing targeted therapies, such as screening small molecules that modulate Rab5B activity or engineering dominant-negative mutants to block pathological signaling.
Studies using recombinant Rab5B have also clarified its crosstalk with other Rabs (e.g., Rab4. Rab7) and its role in autophagy and receptor recycling. As a tool, it aids in mapping protein interaction networks via pull-down assays or structural studies (e.g., X-ray crystallography). Despite progress, questions remain about isoform-specific regulation and tissue-specific adaptors, driving ongoing research into Rab5B's full pathophysiological spectrum.
×
